Desmopressin acetate
Desmopressin acetate 物理性質
- 融点 :
- 170-172°C (dec.)
- 貯蔵温度 :
- −20°C
- 溶解性:
- 酢酸（微量）、メタノール（微量）、水（微量）
- 外見 :
- 個体
- 色:
- ホワイトからオフホワイト
- InChIKey:
- MLSVJHOYXJGGTR-OZEDRGHLNA-N
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 主な危険性 |
Xn |
|
|
| Rフレーズ |
20 |
|
|
| Sフレーズ |
36 |
|
|
| WGK Germany |
3 |
|
|
| HSコード |
3504009000 |
|
|
| 絵表示（GHS） |
 
|
| 注意喚起語 |
|
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H317 |
アレルギー性皮膚反応を起こすおそれ |
感作性、皮膚 |
1 |
警告 |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
| H332 |
吸入すると有害 |
急性毒性、吸入 |
4 |
警告 |
|
P261, P271, P304+P340, P312 |
| H334 |
吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ |
感作性、呼吸器 |
1 |
危険 |
|
P261, P285, P304+P341, P342+P311,P501 |
|
| 注意書き |
| P260 |
粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。 |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
| P314 |
気分が悪い時は、医師の診断/手当てを受けること。 |
|
Desmopressin acetate 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
Desmopressin acetate 化学特性,用途語,生産方法
使用
Antidiuretic.
一般的な説明
Desmopressin acetate(DDAVP, Stimate) is synthetic 1-desamino-8-D-argininevasopressin. Its efficacy, ease of administration (intranasal),long duration of action, and lack of side effects make itthe drug of choice for the treatment of central diabetesinsipidus. It may also be administered intramuscularly orintravenously. It is preferred to vasopressin injectionand oral antidiuretics for use in children. It is indicatedin the management of temporary polydipsia and polyuriaassociated with trauma to, or surgery in, the pituitary region.
臨床応用
Desmopressin, as its acetate salt, is a synthetic analogue of vasopressin in which the Nterminal Cys is devoid of its α-amino function (1-Deamino) and where Arg8 is present as its D-isomer (D-Arg8), thus the commercial acronym DDAVP. The presence of D-Arg and
the absence of the N-terminal amine in the desmopressin structure have increased its half-life
such that it is available for oral, parenteral, or nasal use. It is used by all three of these routes
of administration to prevent or control polydipsia (excessive thirst), polyuria, and dehydration of
patients with diabetes insipidus caused by a deficiency of vasopressin. It also has been
approved for the treatment of nocturnal enuresis (bed-wetting), which is believed to be caused
by an absence of the normal night time rise in vasopressin levels.
Desmopressin is known to cause an increase in both plasma factor VIII (antihemophilic factor)
and plasminogen activator. It therefore is approved by the U.S. FDA for use, parenterally and
nasally, in reducing spontaneous or trauma-induced bleeding episodes in patients with
hemophilia A and type I Von Willebrand's disease, provided that their plasma factor VIII activity is greater than 5%. Stimate, the nasal spray used in treating patients with hemophilia A and
type I Von Willebrand's disease, is 15-fold the concentration of DDAVP nasal spray; the latter is
used in treating diabetes insipidus.
安全性
Desmopressin is generally well-tolerated in most patients. There are a few instances where patients require monitoring for adverse effects of the drug. Patients receiving desmopressin need monitoring for the occurrence of hyponatremia. Symptoms of hyponatremia include nausea, confusion, or altered mental status. As patients age, they should also be continually monitored for declining renal function, as the therapeutic index and clearance of the drug will change according to the renal function. There is no known antidote to an overdose of desmopressin. The most worrisome complication to result from an overdose is water intoxication. This condition would result in a delayed loss of consciousness and seizures in some instances. Patients require immediate admission to the intensive care unit to be monitored and have electrolyte correction.
Desmopressin acetate 上流と下流の製品情報
原材料
準備製品
Desmopressin acetate 生産企業
Global( 234)Suppliers
16789-98-3()キーワード:
- 16789-98-3
- DESMOPRESSIN MONOACETATE
- DESMOPRESSIN ACETATE
- DESMOPRESSIN ACETATE SALT
- DESMORESSIN ACETATE
- Mpr-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2(S-S:1-5)
- 1-(3-Mercaptopropionic acid)-8-D-arginine-vasopressin diacetate
- 1-Deamino-8-D-arginine-vasopressin diacetate
- DDAVP
- Desmopressin (ADH)
- [deamino-Cys1, D-Arg8]-Vasopressin hydrate acetate salt
- DDAVP, Desmopressin
- LKT Desmopressin
- Mpr-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2(S-S:1-6)
- 1-[4-(2-amino-2-keto-ethyl)-7-(3-amino-3-keto-propyl)-10-(benzyl)-13-(4-hydroxybenzyl)-3,6,9,12,15-pentaketo-18,19-dithia-2,5,8,11,14-pentazacycloicosane-1-carbonyl]-N-[1-[(2-amino-2-keto-ethyl)carbamoyl]-4-guanidino-butyl]pyrrolidine-2-carboxamide
- N-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[4-(2-amino-2-oxoethyl)-7-(3-amino-3-oxopropyl)-13-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-10-(phenylmethyl)-18,19-dithia-2,5,8,11,14-pentazacycloicosane-1-carbonyl]pyrrolidine-2-carboxamide
- N-[1-[(2-azanyl-2-oxo-ethyl)amino]-5-[bis(azanyl)methylideneamino]-1-oxo-pentan-2-yl]-1-[[4-(2-azanyl-2-oxo-ethyl)-7-(3-azanyl-3-oxo-propyl)-13-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-10-(phenylmethyl)-18,19-dithia-2,5,8,11,14-pentazacycloicos-1-yl]carbonyl]pyrrolidine-2-carboxamide
- DesMopressin (diacetate)
- DDAVP ACETATE
- [DEAMINO-CYS1,D-ARG8]-VASOPRESSIN ACETATE SALT
- 3-MERCAPTOPROPIONYL-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2 ACETATE SALT
- N-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(p
- Desmopressin Acetate(1:2)
- Desmopressinum
- DesmopressinAcetate(DDAVP)
- Desmopressin acetate USP/EP/BP
- Desmopressin(DDAVP) acetate